{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:07:05Z","timestamp":1777446425752,"version":"3.51.4"},"reference-count":87,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/mcg.0b013e31827559a3","type":"journal-article","created":{"date-parts":[[2013,1,19]],"date-time":"2013-01-19T11:56:49Z","timestamp":1358596609000},"page":"205-211","source":"Crossref","is-referenced-by-count":16,"title":["Rifaximin in the Treatment of Irritable Bowel Syndrome"],"prefix":"10.1097","volume":"47","author":[{"given":"David J.","family":"Farrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210305","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJMe1011211","article-title":"Antibiotic therapy for the irritable bowel syndrome.","volume":"364","author":"Tack","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-6-20210305","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/j.gastro.2007.04.005","article-title":"The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects.","volume":"133","author":"Kassinen","year":"2007","journal-title":"Gastroenterology"},{"key":"R3-6-20210305","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/gut.2006.108712","article-title":"Small intestinal bacterial overgrowth in patients with irritable bowel syndrome.","volume":"56","author":"Posserud","year":"2007","journal-title":"Gut"},{"key":"R5-6-20210305","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s10620-006-9104-6","article-title":"Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.","volume":"51","author":"Pimentel","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R6-6-20210305","first-page":"412","article-title":"Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study.","volume":"98","author":"Pimentel","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R7-6-20210305","first-page":"137","article-title":"Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called chronic amebiasis.","volume":"16","author":"Nayak","year":"1997","journal-title":"Indian J Gastroenterol"},{"key":"R10-6-20210305","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"key":"R11-6-20210305","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2165\/00003495-200565120-00011","article-title":"Rifaximin: a review of its use in the management of travellers diarrhoea.","volume":"65","author":"Robins","year":"2005","journal-title":"Drugs"},{"key":"R12-6-20210305","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/207417a0","article-title":"Effect of rifamycin on protein synthesis.","volume":"207","author":"Calvori","year":"1965","journal-title":"Nature"},{"key":"R13-6-20210305","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1179\/joc.2002.14.3.290","article-title":"Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis.","volume":"14","author":"Brigidi","year":"2002","journal-title":"J Chemother"},{"key":"R14-6-20210305","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1365-2036.2000.00751.x","article-title":"Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.","volume":"14","author":"Di Stefano","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R15-6-20210305","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1365-2036.2007.03259.x","article-title":"High dosage rifaximin for the treatment of small intestinal bacterial overgrowth.","volume":"25","author":"Scarpellini","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-6-20210305","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","article-title":"The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial.","volume":"145","author":"Pimentel","year":"2006","journal-title":"Ann Intern Med"},{"key":"R17-6-20210305","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s10620-011-1728-5","article-title":"Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects.","volume":"56","author":"Pimentel","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R20-6-20210305","doi-asserted-by":"crossref","first-page":"S402","DOI":"10.1093\/clinids\/5.Supplement_3.S402","article-title":"History of the development of rifampin.","volume":"5","author":"Sensi","year":"1983","journal-title":"Rev Infect Dis"},{"key":"R21-6-20210305","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1093\/clinids\/5.Supplement_3.S407","article-title":"Rifampin: mechanisms of action and resistance.","volume":"5","author":"Wehrli","year":"1983","journal-title":"Rev Infect Dis"},{"key":"R22-6-20210305","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","article-title":"In vitro activity and fecal concentration of rifaximin after oral administration.","volume":"44","author":"Jiang","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-6-20210305","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/MOG.0b013e328333dc8d","article-title":"Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.","volume":"26","author":"Koo","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"key":"R24-6-20210305","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis.","volume":"168","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R25-6-20210305","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis.","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"key":"R26-6-20210305","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/j.1572-0241.2000.03368.x","article-title":"Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.","volume":"95","author":"Pimentel","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R27-6-20210305","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.cgh.2009.06.031","article-title":"Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis.","volume":"7","author":"Ford","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R28-6-20210305","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.14309\/00000434-200901001-00002","article-title":"An evidence-based position statement on the management of irritable bowel syndrome.","volume":"104","author":"Brandt","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R29-6-20210305","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10620-007-9839-8","article-title":"Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.","volume":"53","author":"Yang","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R30-6-20210305","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/j.1572-0241.2008.02030.x","article-title":"Small intestinal bacterial overgrowth recurrence after antibiotic therapy.","volume":"103","author":"Lauritano","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R32-6-20210305","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum beta-lactamases: a clinical update.","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"R33-6-20210305","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/163.6.1279","article-title":"Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.","volume":"163","author":"Blumberg","year":"1991","journal-title":"J Infect Dis"},{"key":"R34-6-20210305","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003495-199549030-00009","article-title":"Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.","volume":"49","author":"Gillis","year":"1995","journal-title":"Drugs"},{"key":"R35-6-20210305","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1128\/AAC.00342-08","article-title":"Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.","volume":"52","author":"OConnor","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-6-20210305","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000007297","article-title":"In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.","volume":"46","author":"Marchese","year":"2000","journal-title":"Chemotherapy"},{"key":"R37-6-20210305","first-page":"82","article-title":"Sensitivity to rifaximin and rifampicin of Mycobacterium tuberculosis isolated from guinea pigs treated orally with rifaximin.","volume":"6","author":"Malvisi Stracciari","year":"1987","journal-title":"Chemioterapia"},{"key":"R38-6-20210305","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1469-0691.1997.tb00272.x","article-title":"Selection of rifampin resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin.","volume":"3","author":"Soro","year":"1997","journal-title":"Clin Microbiol Infect"},{"key":"R39-6-20210305","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/jac\/dkn078","article-title":"Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability.","volume":"61","author":"Ruiz","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R40-6-20210305","first-page":"979","article-title":"Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin.","volume":"12","author":"De Leo","year":"1986","journal-title":"Drugs Exp Clin Res"},{"key":"R41-6-20210305","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1469-0691.2004.00997.x","article-title":"Influence of rifaximin treatment on the susceptibility of intestinal gram-negative flora and enterococci.","volume":"10","author":"DuPont","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"R42-6-20210305","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijantimicag.2008.02.002","article-title":"Molecular and phenotypic traits of in vitro-selected mutants of Bifidobacterium resistant to rifaximin.","volume":"31","author":"Vitali","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"R43-6-20210305","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1179\/joc.2005.17.4.380","article-title":"Incidence of cross-resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey.","volume":"17","author":"Senol","year":"2005","journal-title":"J Chemother"},{"key":"R44-6-20210305","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jinf.2010.11.004","article-title":"Rifaximin intake leads to emergence of rifampin-resistant staphylococci.","volume":"62","author":"Valentin","year":"2011","journal-title":"J Infect"},{"key":"R46-6-20210305","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1128\/AM.20.5.810-814.1970","article-title":"Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis.","volume":"20","author":"David","year":"1970","journal-title":"Appl Microbiol"},{"key":"R48-6-20210305","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/bmj.38971.587222.AB","article-title":"Extensively drug resistant tuberculosis.","volume":"333","author":"Lawn","year":"2006","journal-title":"BMJ"},{"key":"R49-6-20210305","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1126\/science.1061861","article-title":"Responding to market failures in tuberculosis: a model to increase access to drugs and treatment.","volume":"293","author":"Gupta","year":"2001","journal-title":"Science"},{"key":"R50-6-20210305","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0140-6736(04)15496-2","article-title":"Programmes and principles in treatment of multidrug-resistant tuberculosis.","volume":"363","author":"Mukherjee","year":"2004","journal-title":"Lancet"},{"key":"R51-6-20210305","doi-asserted-by":"crossref","first-page":"e6914","DOI":"10.1371\/journal.pone.0006914","article-title":"Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.","volume":"4","author":"Johnston","year":"2009","journal-title":"PLoS ONE"},{"key":"R53-6-20210305","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMc0706556","article-title":"Treatment outcomes in extensively resistant tuberculosis.","volume":"359","author":"Chan","year":"2008","journal-title":"N Engl J Med"},{"key":"R54-6-20210305","first-page":"423","article-title":"Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.","volume":"133","author":"Mitchison","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"R55-6-20210305","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJM199302253280802","article-title":"Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.","volume":"328","author":"Goble","year":"1993","journal-title":"N Engl J Med"},{"key":"R56-6-20210305","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0016-5085(81)90644-2","article-title":"Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations.","volume":"81","author":"Viscidi","year":"1981","journal-title":"Gastroenterology"},{"key":"R57-6-20210305","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1348-0421.1981.tb00036.x","article-title":"Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults.","volume":"25","author":"Nakamura","year":"1981","journal-title":"Microbiol Immunol"},{"key":"R58-6-20210305","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1056\/NEJM198901263200402","article-title":"Nosocomial acquisition of Clostridium difficile infection.","volume":"320","author":"McFarland","year":"1989","journal-title":"N Engl J Med"},{"key":"R59-6-20210305","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/CMR.18.2.247-263.2005","article-title":"Clostridium difficile toxins: mechanism of action and role in disease.","volume":"18","author":"Voth","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"R60-6-20210305","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2307\/30145589","article-title":"Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991.","volume":"15","author":"Olson","year":"1994","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R61-6-20210305","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJMcp011603","article-title":"Clinical practice. Antibiotic-associated diarrhea.","volume":"346","author":"Bartlett","year":"2002","journal-title":"N Engl J Med"},{"key":"R62-6-20210305","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1017\/S0195941700026072","article-title":"The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences.","volume":"28","author":"OBrien","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R63-6-20210305","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ajic.2006.06.004","article-title":"Implications of the changing face of Clostridium difficile disease for health care practitioners.","volume":"35","author":"McFarland","year":"2007","journal-title":"Am J Infect Control"},{"key":"R64-6-20210305","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA).","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R65-6-20210305","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1086\/430311","article-title":"Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.","volume":"40","author":"Musher","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R66-6-20210305","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijantimicag.2009.09.012","article-title":"Antimicrobial resistance in Clostridium difficile.","volume":"34","author":"Huang","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"R67-6-20210305","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1756283X10372985","article-title":"Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.","volume":"3","author":"Basu","year":"2010","journal-title":"Therap Adv Gastroenterol"},{"key":"R68-6-20210305","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1128\/AAC.00688-10","article-title":"In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with travelers diarrhea and Clostridium difficile.","volume":"55","author":"Farrell","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R69-6-20210305","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1086\/596315","article-title":"High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.","volume":"48","author":"Curry","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R70-6-20210305","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/ibd.20500","article-title":"Clostridium difficile and inflammatory bowel disease.","volume":"14","author":"Issa","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"R71-6-20210305","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CMR.00081-09","article-title":"Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.","volume":"23","author":"David","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"R72-6-20210305","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jcp.14.4.385","article-title":"Methicillin-resistant staphylococci.","volume":"14","author":"Barber","year":"1961","journal-title":"J Clin Pathol"},{"key":"R73-6-20210305","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections in the United States.","volume":"298","author":"Klevens","year":"2007","journal-title":"JAMA"},{"key":"R74-6-20210305","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1128\/AAC.42.5.1303","article-title":"Historical yearly usage of vancomycin.","volume":"42","author":"Kirst","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R75-6-20210305","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1086\/653518","article-title":"Staphylococcus aureus: methicillin-susceptible S. aureus to methicillin-resistant S. aureus and vancomycin-resistant S. aureus.","volume":"51","author":"Rehm","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R76-6-20210305","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1128\/AAC.44.9.2276-2285.2000","article-title":"Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.","volume":"44","author":"Cui","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R77-6-20210305","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa025025","article-title":"Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene.","volume":"348","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"R78-6-20210305","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"R79-6-20210305","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMra035415","article-title":"Treatment of infections associated with surgical implants.","volume":"350","author":"Darouiche","year":"2004","journal-title":"N Engl J Med"},{"key":"R80-6-20210305","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/39.2.235","article-title":"Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin.","volume":"39","author":"Drancourt","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"R81-6-20210305","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1128\/AAC.00437-10","article-title":"An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.","volume":"54","author":"Cui","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R82-6-20210305","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/clinids\/7.4.504","article-title":"Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes.","volume":"7","author":"Frasch","year":"1985","journal-title":"Rev Infect Dis"},{"key":"R83-6-20210305","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R84-6-20210305","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R85-6-20210305","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1128\/CMR.2.Suppl.S118","article-title":"Global epidemiology of meningococcal disease.","volume":"2","author":"Schwartz","year":"1989","journal-title":"Clin Microbiol Rev"},{"key":"R86-6-20210305","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1699-0463.1998.tb01379.x","article-title":"Population genetics and molecular epidemiology of Neisseria meningitidis.","volume":"106","author":"Caugant","year":"1998","journal-title":"APMIS"},{"key":"R88-6-20210305","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R89-6-20210305","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s10096-005-1297-7","article-title":"Prophylactic use of antibiotics for prevention of meningococcal infections: systematic review and meta-analysis of randomised trials.","volume":"24","author":"Fraser","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R90-6-20210305","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3201\/eid1106.050143","article-title":"Rifampin-resistant meningococcal disease.","volume":"11","author":"Rainbow","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"R91-6-20210305","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/00006454-199611000-00012","article-title":"Evaluation of the use of mass chemoprophylaxis during a school outbreak of enzyme type 5 serogroup B meningococcal disease.","volume":"15","author":"Jackson","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"R92-6-20210305","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/infdis\/124.2.172","article-title":"Effectiveness of rifampin in eradicating the meningococcal carrier state in a relatively closed population: emergence of resistant strains.","volume":"124","author":"Weidmer","year":"1971","journal-title":"J Infect Dis"},{"key":"R93-6-20210305","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01739006","article-title":"First recorded outbreaks of meningococcal disease in the Israel Defence Force: three clusters due to serogroup C and the emergence of resistance to rifampicin.","volume":"22","author":"Almog","year":"1994","journal-title":"Infection"},{"key":"R94-6-20210305","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eimc.2010.07.016","article-title":"Antimicrobial susceptibility of Neisseria meningitidis strains isolated from meningitis cases in Brazil from 2006 to 2008.","volume":"29","author":"Gorla","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"R95-6-20210305","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1128\/AAC.38.6.1256","article-title":"Molecular characterization of rifampin-resistant Neisseria meningitidis.","volume":"38","author":"Carter","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"R96-6-20210305","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/jac\/47.2.219","article-title":"Rifampicin-resistant meningococci causing invasive disease: detection of point mutations in the rpoB gene and molecular characterization of the strains.","volume":"47","author":"Stefanelli","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"R97-6-20210305","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1469-0691.2009.02783.x","article-title":"Molecular characterization of resistance to rifampicin in clinical isolates of Neisseria meningitidis.","volume":"15","author":"Skoczynska","year":"2009","journal-title":"Clin Microbiol Infect"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004836-201303000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:28:43Z","timestamp":1618036123000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004836-201303000-00006"}},"subtitle":["Is There a High Risk for Development of Antimicrobial Resistance?"],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e31827559a3","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}